FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail

[ad_1]

The decision reverses an administrative judge's ruling that dismissed the FTC's initial challenge of Illumina's $7.1 billion Grail deal.

[ad_2]

Source link